B+
Bull case
25%
Probability
Target price
$4.00
+129.9% vs current
CMMB
Chemomab TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$1.50
-13.8% vs current
B-
Bear case
30%
Probability
Target price
$0.50
-71.3% vs current
AI sentiment snapshot
Latest data as of 2026-04-17
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+53.8
Score
AI commentary
Evidence improved materially after checking newer primary sources, but the name still fits a cautious monitoring setup rather than a high-conviction long. Deterministic priors were neutral with weak catalyst density, and the real unlock is external financing/partner validation more than another abstract or poster.
RankAlpha Sentiment Codex - 2026-04-17
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-06-30catalystRunway update reduces immediate distress but not Phase 3 funding needHigh impact
Year-end 2025 cash was $10.4M and management guided runway through the end of Q1 2027, which helps near-term survival optics for a sub-$12M market cap name, though the stock likely still discounts the need for additional capital to launch Phase 3 [#6-K-2026-03-19].
2026-12-31eventStrategic partner or financing package for PSC Phase 3High impact
Management says discussions with strategic partners continue to advance while it progresses activities required for timely initiation of the PSC Phase 3 trial; a credible funding package would be the clearest re-rating trigger, while failure to secure one would likely keep the stock pinned near cash value [#6-K-2026-03-19].
2027-03-31catalystPhase 3 program de-risking from FDA-aligned design and follow-on readiness workHigh impact
Chemomab has FDA alignment on a single pivotal PSC study without liver biopsies or confirmatory studies, and later said FDA agreed with its proposed CMC strategy while allowing additional animal toxicology work to run in parallel with Phase 3; that lowers execution friction, but value creation still depends on actual trial launch and eventual clinical-event validation [#PR-2025-02-19] [#6-K-2026-03-19].
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-17 • Updated nightlySource: Internal modelMethodology